DK3362449T3 - Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose - Google Patents
Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose Download PDFInfo
- Publication number
- DK3362449T3 DK3362449T3 DK16781455.7T DK16781455T DK3362449T3 DK 3362449 T3 DK3362449 T3 DK 3362449T3 DK 16781455 T DK16781455 T DK 16781455T DK 3362449 T3 DK3362449 T3 DK 3362449T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- disorders associated
- sibiriline
- derivatives
- Prior art date
Links
- 230000001413 cellular effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000021597 necroptosis Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306624 | 2015-10-13 | ||
| PCT/EP2016/074638 WO2017064217A1 (en) | 2015-10-13 | 2016-10-13 | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3362449T3 true DK3362449T3 (da) | 2021-07-19 |
Family
ID=54337712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16781455.7T DK3362449T3 (da) | 2015-10-13 | 2016-10-13 | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10426758B2 (da) |
| EP (1) | EP3362449B1 (da) |
| DK (1) | DK3362449T3 (da) |
| ES (1) | ES2885474T3 (da) |
| PL (1) | PL3362449T3 (da) |
| WO (1) | WO2017064217A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020022423A2 (pt) | 2018-05-03 | 2021-02-02 | Rigel Pharmaceuticals, Inc. | composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para fabricar o composto |
| SG11202010915XA (en) | 2018-05-03 | 2020-12-30 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| CN111978311B (zh) * | 2019-05-21 | 2024-05-31 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| BR112022002580A2 (pt) | 2019-09-06 | 2022-07-19 | Rigel Pharmaceuticals Inc | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos |
| WO2021046437A1 (en) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
| JP7395730B2 (ja) | 2019-11-07 | 2023-12-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ヘテロ環式ｒｉｐ１阻害化合物 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| US20240116923A1 (en) * | 2021-01-25 | 2024-04-11 | Seabelife | Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| CN120265280A (zh) | 2022-12-02 | 2025-07-04 | 海洋生命公司 | 调节性坏死抑制剂与n-乙酰半胱氨酸的协同组合 |
| WO2025078659A1 (en) | 2023-10-12 | 2025-04-17 | Seabelife | Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| HUE027546T2 (en) | 2003-08-29 | 2016-10-28 | Brigham & Womens Hospital Inc | Hydantoin derivatives as cell necrosis inhibitors |
| WO2008060907A2 (en) | 2006-11-10 | 2008-05-22 | Bristol-Myers Squibb Company | Pyrrolo-pyridine kinase inhibitors |
| WO2011140164A1 (en) * | 2010-05-06 | 2011-11-10 | Merck Sharp & Dohme Corp. | Aza-indole derivatives useful as modulators of faah |
| DK2935248T3 (da) * | 2012-12-21 | 2018-04-23 | Plexxikon Inc | Forbindelser og fremgangsmåde til kinasemodulering og indikationer derfor |
| TW201613916A (en) * | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| DK3362450T3 (da) * | 2015-10-13 | 2020-09-14 | Inst Nat Sante Rech Med | N1- og N7-substituerede sibirilin-derivater og anvendelse deraf som inhibitorer af cellulær nekroptose |
-
2016
- 2016-10-13 ES ES16781455T patent/ES2885474T3/es active Active
- 2016-10-13 US US15/768,388 patent/US10426758B2/en active Active
- 2016-10-13 WO PCT/EP2016/074638 patent/WO2017064217A1/en active Application Filing
- 2016-10-13 PL PL16781455T patent/PL3362449T3/pl unknown
- 2016-10-13 EP EP16781455.7A patent/EP3362449B1/en active Active
- 2016-10-13 DK DK16781455.7T patent/DK3362449T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| US10426758B2 (en) | 2019-10-01 |
| WO2017064217A1 (en) | 2017-04-20 |
| EP3362449A1 (en) | 2018-08-22 |
| PL3362449T3 (pl) | 2021-12-13 |
| US20180325876A1 (en) | 2018-11-15 |
| ES2885474T3 (es) | 2021-12-13 |
| EP3362449B1 (en) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| DK3325509T3 (da) | Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| HUE070659T2 (hu) | KDM1A inhibitor és annak felhasználása terápiában | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3395353T3 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
| DK3102189T3 (da) | Sammensætning og fremgangsmåde til at fremme søvn | |
| DK3395359T3 (da) | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3325618T3 (da) | Hidtil ukendte trypsin-isoformer og anvendelse deraf | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
| IL247435A0 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| DK3275453T3 (da) | Farmaceutisk sammensætning med silibinin og ve | |
| DK3187178T3 (da) | Sammensætning og lægemidler til reducering af lokaliseret fedt og kropsvægt og anvendelse heraf | |
| DK3157532T3 (da) | Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet | |
| DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri | |
| HUE057216T2 (hu) | Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében | |
| DK3529234T3 (da) | Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser |